163 related articles for article (PubMed ID: 25931811)
1. Clinicopathological significance and potential drug targeting of CDH1 in lung cancer: a meta-analysis and literature review.
Yu Q; Guo Q; Chen L; Liu S
Drug Des Devel Ther; 2015; 9():2171-8. PubMed ID: 25931811
[TBL] [Abstract][Full Text] [Related]
2. The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review.
Zeng W; Zhu J; Shan L; Han Z; Aerxiding P; Quhai A; Zeng F; Wang Z; Li H
Drug Des Devel Ther; 2015; 9():2149-57. PubMed ID: 25926721
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance and potential drug target of T-cadherin in NSCLC.
Wang Z; Wang B; Guo H; Shi G; Hong X
Drug Des Devel Ther; 2015; 9():207-16. PubMed ID: 25565774
[TBL] [Abstract][Full Text] [Related]
5. Role of CDH1 promoter polymorphism and DNA methylation in bladder carcinogenesis: a meta-analysis.
Wang Y; Kong CZ; Zhang Z; Yang CM; Li J
DNA Cell Biol; 2014 Apr; 33(4):205-16. PubMed ID: 24491043
[TBL] [Abstract][Full Text] [Related]
6. Role of CDH1 promoter methylation in colorectal carcinogenesis: a meta-analysis.
Li YX; Lu Y; Li CY; Yuan P; Lin SS
DNA Cell Biol; 2014 Jul; 33(7):455-62. PubMed ID: 24684676
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
Xu L; Lan H; Su Y; Li J; Wan J
Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
[TBL] [Abstract][Full Text] [Related]
8. The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis.
Wang Q; Wang B; Zhang YM; Wang W
J Ovarian Res; 2016 Apr; 9():23. PubMed ID: 27067410
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
10. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer.
Ling ZQ; Li P; Ge MH; Zhao X; Hu FJ; Fang XH; Dong ZM; Mao WM
Int J Mol Med; 2011 May; 27(5):625-35. PubMed ID: 21373750
[TBL] [Abstract][Full Text] [Related]
12. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review.
Wu X; Wu G; Yao X; Hou G; Jiang F
Drug Des Devel Ther; 2016; 10():699-709. PubMed ID: 26929601
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis.
Li Y; Zhu M; Zhang X; Cheng D; Ma X
Drug Des Devel Ther; 2015; 9():1785-96. PubMed ID: 25848215
[TBL] [Abstract][Full Text] [Related]
14. The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review.
Yan W; Xu N; Han X; Zhou XM; He B
Sci Rep; 2016 Jan; 6():19303. PubMed ID: 26796853
[TBL] [Abstract][Full Text] [Related]
15. The clinicopathological significance and potential drug target of E-cadherin in NSCLC.
Zhong K; Chen W; Xiao N; Zhao J
Tumour Biol; 2015 Aug; 36(8):6139-48. PubMed ID: 25758052
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis.
Chen F; Huang T; Ren Y; Wei J; Lou Z; Wang X; Fan X; Chen Y; Weng G; Yao X
BMC Urol; 2016 Aug; 16(1):52. PubMed ID: 27578166
[TBL] [Abstract][Full Text] [Related]
17. The association, clinicopathological significance, and diagnostic value of
Shen Z; Zhou C; Li J; Deng H; Li Q; Wang J
Onco Targets Ther; 2016; 9():6763-6773. PubMed ID: 27826202
[TBL] [Abstract][Full Text] [Related]
18. Aberrant promoter methylation of cell adhesion-related genes associated with clinicopathologic features in non-small cell lung cancer in China.
Xu PW; Xu HY; Liu XN; Zhang CY; Tan C; Chen CM; Zhang H; Jin YT
Cancer Biomark; 2013; 13(2):115-22. PubMed ID: 23838140
[TBL] [Abstract][Full Text] [Related]
19. Association between
Fan Z; Chen R; Li M; Gu J; Li X; Wei W
Expert Rev Mol Diagn; 2022 Sep; 22(9):895-903. PubMed ID: 36254608
[TBL] [Abstract][Full Text] [Related]
20. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]